



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07K 13/00, A61K 37/02 C12P 21/02, C12N 15/70	A1	(11) International Publication Number: WO 92/13885 (43) International Publication Date: 20 August 1992 (20.08.92)
(21) International Application Number: PCT/US92/00662 (22) International Filing Date: 5 February 1992 (05.02.92) (30) Priority data: 649,568 5 February 1991 (05.02.91) US (71) Applicant: UNIVERSITY OF MARYLAND [US/US]; College Park, 4312 Knox Road, College Park, MD 20742 (US). (72) Inventor: VEERAPANDIAN, Balasubramanian ; 13508 Glen Mill Road, Rockville, MD 20850 (US). (74) Agents: HIGHET, David, W. et al.; Venable, Baetjer, Howard & Civiletti, 1201 New York Avenue, N.W., Suite 110, Washington, DC 20005 (US).		(81) Designated States: AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH (European patent), CI (OAPI patent), CM (OAPI patent), CS, DE (European patent), DK (European patent), ES (European patent), FI, FR (European patent), GA (OAPI patent), GB (European patent), GN (OAPI patent), GR (European patent), HU, IT (European patent), JP, KP, KR, LK, LU (European patent), MC (European patent), MG, ML (OAPI patent), MN, MR (OAPI patent), MW, NL (European patent), NO, PL, RO, RU, SD, SE (European patent), SN (OAPI patent), TD (OAPI patent), TG (OAPI patent). Published <i>With international search report.</i>
(54) Title: MODIFIED INTERLEUKIN-1 β (57) Abstract The present invention relates to modified forms of IL-1β with altered IL-1 activity. The modified IL-1β is the result of mutations which affect amino acids in the beta barrel portion of the IL-1β structural formula. The invention also relates to expression systems that will produce the modified IL-1β polypeptides, and methods of treating susceptible diseases with the modified IL-1β polypeptides.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	ML	Mali
AU	Australia	FR	France	MN	Mongolia
BB	Barbados	GA	Gabon	MR	Mauritania
BE	Belgium	GB	United Kingdom	MW	Malawi
BF	Burkina Faso	GN	Guinea	NL	Netherlands
BG	Bulgaria	GR	Greece	NO	Norway
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IE	Ireland	RO	Romania
CA	Canada	IT	Italy	RU	Russian Federation
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark	MG	Madagascar		
ES	Spain				

-1-

5 TITLE OF THE INVENTIONMODIFIED INTERLEUKIN-1 β BACKGROUND OF THE INVENTION

10

The term interleukin-1 (IL-1) refers to two different polypeptides (IL-1 α and IL-1 β). These two polypeptides possess a wide variety of both immunologic and nonimmunologic activities. IL-1 α and IL-1 β are distinct gene products. However, these two polypeptides recognize the same receptor and exhibit the same biological properties. IL-1 is produced in response to a variety of conditions including inflammatory agents, toxins, infection and clotting components. The primary amino acid sequence of human IL-1 α and IL-1 β have been reported (Auron et al., Proc. Natl. Acad. Sci. USA, 81, 7907 (1984); and March et al., Nature 315, 641 (1985), respectively). Furthermore, The entire human gene for each form of IL-1 has been cloned and sequenced (Clark et al., Nucleic Acids Res. 14, 7897 (1986); Furutani et al., Nucleic Acids Res. 14, 3167 (1986)).

IL-1 is a small protein of molecular weight about 17.5 kilodaltons, which induces sleep and systemic acute-phase responses including fever, increased hepatic acute-phase protein synthesis, neutrophilia, hypozincemia, hypoferremia and increased levels of hormones when injected into experimental animals. Although IL-1 α and IL-1 β have been shown to have distinct primary amino acid sequences (only about 26% amino acid sequence homology), these two polypeptides have been shown to be structurally related by molecular modeling, receptor recognition and crystallographic analysis.

40

-2-

The three dimensional structure of IL-1 β has 12 β strands which form a complex of hydrogen bonds as shown by analysis of the tertiary structure of crystallized human IL-1 β and computerized molecular modeling. The basic structure is similar to a tetrahedron with an interior filled by hydrophobic side chains. Therefore, the interior of IL-1 β is strongly hydrophobic with no charged amino acids.

IL-1 β is the more prominent of the two known gene products for IL-1, as evidenced by the greater amount of IL-1 β found in culture supernatants and various human body fluids. Furthermore, the amount of IL-1 β mRNA found in activated cells is usually about 10 to 50 times greater than the amount of IL-1 α found in these same cells. IL-1 β is more readily secreted from activated cells, whereas IL-1 α remains cell-associated.

IL-1 β was originally cloned from human blood monocytes, and has subsequently been cloned in cows, rabbits, rats and mice. IL-1 α was originally cloned from the mouse macrophage cell line P388D, and has subsequently been cloned in humans, rabbits and rats.

Several peptides which exhibit some of the same biological properties as IL-1 have been either synthesized (Antoni et al., J. Immunol. 137, 3201 (1986)) or produced by recombinants DNA methods (Rosenwasser et al., Proc. Natl. Acad. Sci. USA 83, 1 (1986)). However, the specific activities of these peptides are low, and the peptides do no block the receptor binding of mature IL-1. Conventional theories suggest that both the N-terminal and C-terminal amino acids of

-3-

IL-1 are involved in its receptor binding (Dinarello, Advances in Immunology 44, 153 (1989)).

The histidine residue at position 147 has been substituted by site-specific mutation with a resulting loss of biological activity and receptor binding (MacDonald et al., FEBS Lett. 209, 295 (1986)). However, this histidine residue is located on the surface of the IL-1 β molecule.

Other mutations of IL-1 β N-terminal amino acids have also resulted in altered biological activity and receptor binding (Horuk et al., J. Biol. Chem. 262, 16275 (1987)). These mutations also suggest that the N-terminal amino acids of IL-1 β play an important role by direct interaction with receptor-binding domains.

However, the IL-1 β mutants produced to date have not been found to be significantly effective in minimizing, or more importantly, antagonizing the biological activities of IL-1. Such an antagonist of IL-1 would be particularly useful in the treatment of patients with bacterial infection, injury or chronic inflammatory disease.

SUMMARY OF THE INVENTION

The present invention overcomes the inherent limitations of previously proposed mutants of IL-1 by providing modified structures of IL-1 β which result in either IL-1 agonist or antagonist activity.

In accordance with the invention, the modified IL-1 β with altered IL-1 activity comprises the IL-1 polypeptide with at least one mutation to the beta barrel portion of the IL-1 β structural formula. The invention also relates to

-4-

expression systems which will produce the modified IL-1 β polypeptides, as well as methods of treating diseases by administering an effective amount of the modified IL-1 β polypeptides.

5

BRIEF DESCRIPTION OF THE DRAWINGS

The various aspects, advantages and novel features of the present invention will be more clearly understood from the following detailed description when read in conjunction with the appended drawings in which:

10

Figs. 1A and 1B are schematic depictions of the IL-1 β molecule and its receptor.

15

Fig. 2 is a computerized representation of the molecular structural formula of IL-1 β .

20

DETAILED DESCRIPTION OF THE INVENTION

In order to provide a clear and consistent understanding of the specification and the claims, the following definitions are provided:

25

Beta barrel: A portion of the molecular structural formula of IL-1 β . The beta barrel is composed of twelve antiparallel β strands exhibiting a pseudo three-fold symmetry. The beta barrel has a concentration of polar residues on both of its ends. The beta barrel of interleukin-1 β is depicted in the computerized models shown in Figs. 2 and 3.

30

-5-

Cell Culture: A proliferating mass of cells which may be in an undifferentiated or differentiated state. As used herein "cell line", and "cell culture" are used interchangeably and all such designations include progeny. Thus "transformants" or "transformed cells" includes the primary subject cell and cultures derived therefrom without regard for the number of transfers. It is also understood that all progeny may not be precisely identical to DNA content, due to deliberate or inadvertent mutations. Mutant progeny which have the same functionality as screened for in the originally transformed cell, are included. Where distinct designations are intended, it will be clear from the context.

Coding Sequence: A deoxyribonucleotide sequence which when transcribed and translated results in the formation of a cellular protein, or a ribonucleotide sequence which when translated results in the formation of a cellular protein.

Control Sequences: Refers to DNA sequence necessary for the expression of an operably linked coding sequence in a particular host organism. The control sequences which are suitable for procaryotes, for example, include a promoter, optionally an operator sequence, a ribosome binding site, and possibly, other as yet poorly understood, sequences. Eucaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.

-6-

Expression System: Refers to DNA sequences containing a desired coding sequence and control sequences in operable linkage, so that hosts transformed with these sequences are capable of producing the encoded proteins. In order to effect transformation, the expression system may be included on a vector; however, the relevant DNA may then also be integrated into the host chromosome.

Gene: A discrete nucleic acid region which is responsible for a discrete cellular product.

Operably Linked: Refers to juxtaposition such that the normal function of the components can be performed. Thus, a coding sequence "operably linked" to control sequences refers to a configuration wherein the coding sequence can be expressed under the control of these sequences.

Promoter: The 5'- flanking, non-coding sequence adjacent a coding sequence which is involved in the initiation of transcription of the coding sequence.

With the above definitions in mind, the present invention broadly relates to modified or mutated forms of IL-1 β . Some of the modifications result in peptide compositions which cause biological effects that mimic the biological effects of interleukin-1 (i.e. IL-1 agonists). Other modifications result in compositions which cause biological effects which nullify the biological effects of interleukin-1 (i.e. IL-1 antagonists). However, all of the resulting

-7-

peptide compositions differ from IL-18 by a modification or mutation to at least one amino acid in the beta barrel portion of the IL-18 structure.

5 The effect of the modification or mutation to an amino acid in the beta barrel of the IL-18 structure may be either direct or indirect. Direct effects are modifications or mutations of the target amino acid in the beta barrel.
10 Indirect effects to an amino acid in the beta barrel are modifications or mutations of at least one amino acid other than the target amino acid in the beta barrel.

15 A modification which results in an indirect effect to an amino acid in the beta barrel is a modification to an amino acid proximate to the target amino acid. However, the proximate amino acid that is modified to produce an indirect effect may be an amino acid which is not in the
20 beta barrel, or an amino acid which is also in the beta barrel.

 A modification which results in an indirect effect to a target amino acid in the beta barrel may be a modification which neutralizes the charge
25 of the target amino acid, neutralizes the acidity or basicity of the target amino acid, effects the hydrophilicity or hydrophobicity of the target amino acid, or alters the steric position of the target amino acid. These same effects are also
30 the result of direct modification of the target amino acid itself.

 The direct modifications of the IL-18 structure which are of particular interest are:

-8-

- 1) A mutation of Glu25 to Ala which inhibits the biological activity of IL-1 β , but still permits binding of the modified polypeptide to the IL-1 receptor.
5
- 2) The mutation of Glu25 to Ala and the mutation of Lys103 to Ala which also inhibits the biological activity of IL-1 β .
10
- 3) The mutation of Glu25 to Ala, Lys103 to Ala, and the mutation of Cys8, Met44, and/or Met148 to either Ala or Gly to inhibit the biological activity of IL-1 β .
15

The indirect modification of the IL-1 β structure which is of particular interest is the mutation of Ser21 to Arg which results in the neutralization of the negative charge of Glu25, thereby inhibiting the biological activity of IL-1 β .
20

The modified interleukins of the present invention (including those listed above) were proposed following close examination of the three dimensional structure of IL-1 β , and review and evaluation of previous attempts to modify the IL-1 β structure to obtain compounds with IL-1 β antagonist activity. This review and evaluation led to the conclusion that IL-1 β binds to its receptor in a manner contrary to conventional receptor binding theory.
25
30

Conventional receptor binding theory suggests that the IL-1 β molecule binds to its receptor at a single point or along a very narrow section of the
35

-9-

molecule. However, the present inventor found that the IL-1 β molecule binds to its receptor in a broad manner, or surface to surface, as depicted in Figs. 1A and 1B. This unconventional surface to surface binding of IL-1 β to its receptor is supported by previous mutations of the IL-1 β molecule, and by the similarities of the molecular structures of IL-1 β , IL-1 α and known IL-1 antagonists.

Previous mutations of the IL-1 β molecule have resulted in inefficient binding of the mutant to the IL-1 receptor (Priestle *et al.*, *EMBO J.* 7, 339 (1988)). However, these previous mutations have been distant from one another, rather than in close proximity. Yet even distant mutations result in inefficient binding of the different mutants to the receptor. Therefore, more than a single point or narrow band of the IL-1 β molecule is binding to the receptor. Instead, a broad surface is binding to a broad surface of the receptor as depicted in Figs. 1A and 1B. Hence, even mutations at sites distant from one another on the binding surface of the IL-1 β molecule will cause similar results of inefficient binding of the IL-1 β molecule to its receptor.

Furthermore, the molecular structures of IL-1 β , IL-1 α and known IL-1 antagonists all have basic similarities. These basic similarities all relate to the beta barrel portion of the molecules. All of these molecules have the unique structural folding which produces the beta barrel structural characteristic. Furthermore, the key amino acid residues of IL-1 β (Glu25, Lys103 and part of the sulfur cluster) are also present at the same locations on the beta barrel of the IL-1 α

-10-

structure, although not at the same locations in the amino acid sequence. However, the known IL-1 antagonists lack these three key amino acid residues.

5 Using this knowledge, the inventor examined the molecular structure of IL-1 β as described in Examples 1 and 2, below. The inventor then found that the surface at the end of the IL-1 β beta barrel was the type of surface that would be
10 appropriate for the necessary surface to surface binding with the receptor.

 Although barrel structures in other molecules are commonly utilized to transport ions, the beta barrel of IL-1 β is too narrow to perform such a
15 task. Also, the inventor noted that there are oppositely charged focal amino acids at the opposite ends of the beta barrel. While a positively charged lysine (Lys103) is located in the beta barrel surface that binds to the
20 receptor, a negatively charged aspartic acid (Glu25) is located at the surface of the beta barrel which is furthest from the receptor (see Figs. 1A and 1B). Also noted was a sulfur cluster of -Cys8-Met44-Met148- which is located in the
25 beta barrel, on the axis between the oppositely charged Lys103 and Glu25.

 It is mutations at these three foci of the beta barrel which result in the modified forms of IL-1 β of the present invention. The mutations may
30 be to the target amino itself or to proximate amino acids in order to affect the target amino acid. The mutations that affect Lys103 or Glu25 at opposite ends of the beta barrel are mutations which nullify the charge of Lys103 and/or Glu25.

-11-

The mutations which affect Glu25 generally result in modified forms of IL-1 β that act to antagonize the effect of IL-1 β , and strongly bind to the IL-1 receptor. These modified forms of IL-1 β maintain the strong receptor binding characteristics of IL-1 β because the mutation affects a target amino acid (Glu25) which is not on the surface of the molecule which binds to the receptor. The antagonist activity of such modified forms of IL-1 β are the result of partial or total neutralization of the negative charge of Glu25.

The neutralization of the negative charge of Glu25 may be accomplished by either direct mutation of the target glutamic acid (Glu25) or mutation of a proximate amino acid to effect the negatively charged Glu25. Direct mutations of Glu25 to neutralize its negative charge include mutations to alanine, glycine, valine, leucine, isoleucine, phenylalanine, (i.e. non polar groups). Of these direct mutations, the preferred mutation is the replacement of Glu25 with alanine (i.e. Ala25). This mutation results in inhibition of the IL-1 β effects of the protein without affecting the protein's binding to the IL-1 receptor. Of the mutations of other amino acids to indirectly affect the target amino acid (Glu25), the preferred mutation is the replacement of the serine at position 21 (Ser21) with an arginine (Arg21). This mutation also causes a neutralization of the negative charge of Glu25 to invalidate the IL-1 β effects of the protein without affecting the protein's binding to the IL-1 receptor.

-12-

However, direct mutations of Glu25 are one of the most preferred embodiments of the invention relating to modified IL-1 β with IL-1 β antagonist properties, because these modifications are the most similar to known, natural IL-1 β antagonists. The known naturally occurring IL-1 β antagonists have a Gln29, neutralized by Arg26.

In addition to the mutations to affect Glu25, mutations to affect Lys103 are also effective to produce modified IL-1 β with IL-1 β antagonist properties. However, direct mutations of Lys103 also have an affect on the binding of the molecule to the IL-1 receptor, because Lys103 is located on the surface of the beta barrel that binds to the receptor. The most effective mutation of Lys103 to produce a modified IL-1 β with antagonist properties is the replacement of Lys103 with alanine (i.e. Ala103). However, this mutation may produce a more potent IL-1 β antagonist when coupled with the direct mutation of Glu25 to Ala25.

Furthermore, complete inhibition of IL-1 β effects is achieved with the two above mutations (Glu25Ala and Lys103Ala) and a mutation of the sulfur cluster (Cys8, Met44, Met148) to alanine and/or glycine. This sulfur cluster is necessary for the strong effects of IL-1 β . Therefore, mutation of this sulfur cluster to alanine and/or glycine completely invalidates IL-1 β agonist activity. Furthermore, it is expected that the degree of inhibition of the IL-1 β effects of the modified IL-1 β molecules may be modulated by mutating only one or two of the amino acids of the sulfur cluster rather than all three amino acids.

-13-

Other compositions also have molecules with a barrel structure which is too narrow to transport ions, and therefore similar mutations to these molecules are expected to have similar results as the mutations to the IL-1 β molecule. Among other compositions, IL-1 α , fibroblast growth factor and tumor necrosis factor are such compositions with molecules exhibiting a barrel structure similar to that of IL-1 β .

All of the above mutations are accomplished by the techniques of site-directed mutagenesis of cloned DNA which are conventional in the art. Such techniques are fully explained in Molecular Cloning, A Laboratory Manual, Second Edition, Sambrook et al., Cold Spring Harbor Laboratory Press 1989, incorporated herein by reference. However, these mutations may also be accomplished by cleaving the IL-1 β gene near the target mutation site, and applying standard polymerase chain reaction (PCR) techniques with mismatched primers. The PCR products (with the desired mutations) are then annealed to the unmutated segments of the cleaved IL-1 β gene.

Having determined that Glu25, Lys103 and the sulfur cluster -Cys8-Met44-Met148 are the important functional areas of the IL-1 β molecule (as explained above), new, smaller agonist and antagonist peptides can be synthesized by utilizing these target areas. One basic form of these synthetic agonist peptides has just the three functional areas of the IL-1 β molecule. Thus, this synthetic agonist peptide has the amino acid sequence designated SEQ ID NO.1, and serves as a substitute for IL-1 β .

-14-

Similarly, any synthetic peptide which contains a lysine (Lys) on one side of the sulfur cluster (-Cys-Met-Met-) and an glutamic acid (Glu) on the other side of the sulfur cluster, even with other amino acid residues inserted between these functional groups, may act as an agonist, and mimic the effects of IL-1 β . These synthetic peptide agonists are small dipole peptides with a sulfur cluster between the dipole, and are produced using standard peptide synthesis techniques. However, once these IL-1 β peptide agonists have been synthesized, conventional degenerative primer techniques may be utilizing to produce the synthetic IL-1 β agonists with the polymerase chain reaction (PCR).

Furthermore, these smaller synthetic peptide agonists can be mutated to produce small synthetic peptide antagonists. The mutations are directed at the same three target locations, namely the aspartic acid which corresponds to Glu25 of IL-1 β , the lysine which corresponds to Lys103, and the sulfur cluster which corresponds to -Cys8-Met44-Met148. However, due to the smaller size of the synthetic peptide, the mutations are preferably direct mutations of the target amino acids rather than mutations of proximate amino acids in order to affect the target amino acid.

Moreover, the sulfur cluster (-Cys-Met-Met-) can be used by itself or in a larger peptide as an enhancer of IL-1 β activity or as IL-1 β agonists. The sulfur cluster will enhance the effects of IL-1 β . Therefore, a smaller molecule which contains this sulfur cluster can act as an enhancer of IL-1 β activity when administered in conjunction with IL-1 β or a synthetic IL-1 β agonist.

-15-

Any of the modified IL-1 β compounds (or small peptide IL-1 β agonists or antagonists, or the sulfur cluster enhancers) can be produced by appropriate expression systems using conventional recombinant nucleotide techniques. The control sequences, expression vectors, and transformation methods are dependent on the type of host cell used to express the gene. Generally, procaryotic, yeast, or mammalian cells are presently useful as hosts. Procaryotic hosts are in general the most efficient and convenient for the production of recombinant proteins. However, eucaryotic cells, and, in particular, mammalian cells are sometimes used for their processing capacity.

The procaryotes most frequently used as hosts are represented by various strains of E. coli. However, other microbial strains may also be used, such as bacilli, for example Bacillus subtilis, various species of Pseudomonas, or other bacterial strains. In such procaryotic systems, plasmid or bacteriophage vectors which contain replication sites and control sequences derived from a species compatible with the host are used. A wide variety of vectors for many procaryotes are known (Sambrook et al., (1989), Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY). Commonly used procaryotic control sequences which are defined herein to include promoters for transcription initiation, optionally with an operator, along with ribosome binding site sequences, include such commonly used promoters as the beta-lactamase (penicillinase) and lactose (lac) promoter systems, the tryptophan (trp) promoter system and the lambda derived PL promoter

-16-

and N-gene ribosome binding site, which has been made useful as a portable control cassette (U.S. Patent No. 4,711,845). However, any available promoter system compatible with procaryotes can be used (Sambrook *et al.*, *supra*).

In addition to bacteria, eucaryotic microbes, such yeast, may also be used as hosts. Laboratory strains of *Saccharomyces cerevisiae*, Baker's yeast, are most used, although a number of other strains are commonly available. Vectors employing the 2 micron origin of replication and, other plasmid vectors suitable for yeast expression are known (Sambrook *et al.*, *supra*). Control sequences for yeast vectors include promoters for the synthesis of glycolytic enzymes. Additional promoters known in the art include the promoter for 3-phosphoglycerate kinase, and those for other glycolytic enzymes, such as glyceraldehyde-3-phosphase dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglycose isomerase, and glucokinase. Other promoters, which have the additional advantage of transcription controlled by growth conditions, are the promoter regions for alcohol dehydrogenase 2, isocytochrome C, acid phosphates, degradative enzymes associated with nitrogen metabolism, and enzymes responsible for maltose and galactose utilization. (See Sambrook *et al.*, *supra*).

It is also believed terminator sequences are desirable at the 3' end of coding sequences. Such terminators are found in the 3' untranslated region following the coding sequences in

-17-

yeast-derived genes. Many of the vectors illustrated contain control sequences derived from the enolase gene containing plasmid peno46 or the LEU2 gene obtained from Yep13, however, any vector
5 containing a yeast compatible promoter, origin or replication and other control sequences is suitable (Sambrook et al., supra).

It is also possible to express genes encoding polypeptides in eucaryotic host cell cultures
10 derived from multicellular organisms (Meth. Enzymol., Vol 58, Academic Press, Orlando (1979)). Useful host cell lines include murine myelomas N51, Vero and HeLa cells, and Chinese hamster ovary (CHO) cells. Expression vectors for
15 such cells ordinarily include promoters and control sequences compatible with mammalian cells such as, for example, the commonly used early and later promoters from Simian Virus 40(SV 40), or other viral promoters such as those derived from
20 polyoma, adenovirus 2, bovine papilloma virus, or avian sarcoma viruses, or immunoglobulin promoters and heat shock promoters (Sambrook et al., supra). General aspects of mammalian cell host system transformations have been described by Axel
25 (U.S. Patent No. 4,399,216).

It now also appears that "enhancer" regions are important in optimizing expression; these are, generally, sequences found upstream of the promoter region. Origins of replication may be
30 obtained, if needed, from viral sources. However, integration into the chromosome is a common mechanism for DNA replication in eucaryotes. Plant cells are also now available as hosts, and control sequences compatible with plant cells such

-18-

as the nopaline synthase promoter and polyadenylation signal sequences are available (Meth. Enzymol., Vol 118, Academic Press, Orlando (1979)).

5 Depending on the host cell used, transformation is done using standard techniques appropriate to such cells. Such techniques include, but are not limited to, calcium treatment
10 employing calcium chloride for procaryotes or other cells which contain substantial cell wall barriers; infection with Agrobacterium tumefaciens for certain plant cells; calcium phosphate precipitation method for mammalian cells without cell walls; and, microprojectile bombardment for
15 many cells including plant cells.

 The compounds of the present invention are purified using conventional techniques as described in Kikumoto et al., Biochem. Biophys. Res. Comm. 147, 315 (1987). Furthermore, the
20 biological activity of these compounds is evaluated by the standard murine (C3H/HeJ) thymocyte proliferation assay as described in Lachman et al., Methods Enzymol. 116, 467 (1985). Other useful tests for the biological activity of
25 these compounds are the fibroblast prostaglandin E₂ production assay and the EL4/9 interleukin-2 production assay. The binding of the compounds of the invention to the IL-1 receptor is assayed by iodinating the compounds with Bolton Hunter
30 reagent and binding the iodinated compounds to EL4/9 cells according to the methods of Dower et al., Nature 324, 266 (1986). In vitro tumor inhibitory activity of the IL-1 β agonists is measured by the methods described in Nakamura et al., Jap. J. Cancer Res. (Gann) 77, 767 (1986).
35

-19-

Briefly, C57BL/6 mice are transplanted with B16 melanoma cells intra-dermally on day 0, the compounds of the present invention in pharmaceutical composition are injected once daily on day 8 through 14, and inhibition rates are calculated on day 15.

The compounds of the present invention (the IL-18 agonists, the IL-18 antagonists, and the IL-18 agonist enhancers) may be either used in a pharmaceutical composition in their respective peptide forms, or may be attached to an appropriate peptide carrier to be used in pharmaceutical compositions. When used as the active ingredient in a pharmaceutical composition, the compounds of the present invention are admixed with an appropriate pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., intravenous, oral or parenteral. The composition may also be administered by means of an aerosol. Although oral dosage forms are not preferred because the active ingredients are peptides which are degraded by enzymes in the gastrointestinal tract, conventional techniques for protecting the peptide from enzymatic digestion may be used. Such conventional techniques include enteric coating of tablets with agents such as mixtures of fats and fatty acids, shellac and shellac derivatives, and cellulose-acetate phthalates. The use of cellulose acetate phthalates is most common and preferred.

-20-

However, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like in the case of oral liquid preparations (such as, for example, suspensions, elixirs and solutions); or carriers such as starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like in the case of oral solid preparations (such as, for example, powders, capsules and tablets). Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be sugar-coated or enteric-coated by standard techniques.

Parental preparations of the active compounds of the present invention are preferred. For parenteral preparations, the carrier will usually comprise sterile water, though other ingredients, for example, to aid solubility or for preservative purposes, may be included; injectable suspensions may also be prepared, in which case appropriate liquid carriers, suspending agents and the like may be employed. The pharmaceutical compositions will generally contain a dosage per unit, e.g., tablet, capsule, powder, injection, teaspoonful and the like, from about 0.01 to about 50 mg/kg, and preferably from about 0.1 to about 10 mg/kg of the active ingredient.

The following examples describe the invention in greater particularity and are intended to be a way of illustrating but not limiting the invention.

-21-

EXAMPLE 1

Crystallization of IL-1 β and
Data Collection

5

Purified recombinant human IL-1 β was supplied by Otsuka Pharmaceuticals, Japan. Crystals were grown by vapor diffusion using the hanging drop technique as described in Gilliland et al., (citation) (1987). These crystals are tetragonal with $a=b=55.14(2)$ Å and $c=76.66(4)$ Å and belong to the enantiomorphic pair of space group $P4_1$ or $P4_3$.

Diffraction X-ray intensity data were collected by using a Siemen's multiwire area detector. The X-ray source was a Rigaku ra200 rotating anode operating at 3.2 kW, equipped with a graphite monochromator. The chamber was set at $2\theta=20^\circ$, where 2θ defines the angle between the normal to the center of the detector face and the undiffracted X-ray beam direction. Chamber to crystal distance was kept as 10 cm and a data set was collected to a resolution of 2.0 Å with a total of 25,706 observations, scaled to give an R_{merge} of 0.05, where

25

$$R_{\text{merge}} = \frac{\sum_i |I_i - \langle I \rangle|}{\sum_i I_i}$$

Of the available 14,207 unique reflections, 11,013 having $I > 2\sigma(I)$ were used for the rest of the analysis and refinement. Reduction of these data to integrated intensities was carried out using the XENGEN software package (Howard et al., 1987).

30

-22-

Heavy Atom Derivatives and Use of Recombinant Technology

5 Of the 16 potential derivative data sets collected, only three were used in the structure solution. All the derivative data sets extended to a resolution of 3 Å. Difference Patterson maps of mercurial and few other derivatives showed a single major site, later to be identified with
10 Cys8.

Interpretation of the single isomorphous map by using this site was difficult and confusing, even though some of the molecule's secondary structural features could be identified. Since
15 IL-18 contains two cysteines, site directed mutagenesis was used to change one of the cysteines to alanine, in order to obtain a new derivative. Recombinant protein was prepared by mutating Cys8 to Ala8 without altering Cys71 and
20 used to make heavy atom derivatives. Mutant derivative crystals were found to be isomorphous with those of wild type protein. Difference Patterson map of this brought out another heavy atom site, later confirmed to be closer to Cys71.

25 Scaling, merging and MIR steps were carried out using PROTEIN (Steigemann, 1974) package. The x and y coordinates of the sites were determined from the Harker section $w=1/2$. Since the space group is an enantiomer of $P4_3$ or $P4_1$, wherein the
30 origin is not defined, the z coordinate of the first site was given an arbitrary value of 0.1. The centric data alone were used (Rossmann, 1960) in order to refine the spatial coordinates, occupancy, atomic temperature, factor, overall
35 scale factor and relative temperature factor of these sites.

-23-

Differences Fourier and cross difference Fourier maps were computed to confirm these major sites and few other minor sites were also identified. Using these sites, native MIR phases were calculated to a resolution of 3.0 Å and computed electron density map showed defined chain directions. Computed minimap defined the boundary of the molecule and showed large amount of solvent space in the crystal lattice.

B.C. Wang's automated package (Wang, B.C., 1985) for solvent flattening was employed to improve the quality of the MIR map and solvent filtering was done at a resolution of 3.0 Å. This procedure improved the phasing, evident from the increase in the average figure of merit from 71% of MIR to 83%. The obtained Fourier map showed clear solvent-protein boundaries along with well defined electron density for extended β -strands.

FRODO (Jones & Thirup 1986), which uses a protein data base of best refined protein structures, was used in order to interpret the electron density map. The skeletons of the map were obtained as 'bones' by connecting a set of points through the centroids of the continuous stretch of density. FRODO allows the obtained skeletons to be identified as probable main chain, possible main chain and side chain. Initially the chain was modelled as poly serine and later modified to the appropriate residues. Whenever the connectivity showed a loop or a turn, database search within FRODO was used to place the fragments in the background, a helping aid in building the difficult parts of the model. The twist observed in the β -strands ambiguously fixed

-24-

the spacegroup of this system as $P4_3$ and not $P4_1$, confirming the model suggested by Priestle et al., (citation) 1988.

5 Molecular Dynamics and Conventional Refinement

This 3.0 Å model was refined initially with X-PLOR (Brunger, 1988), which employs molecular dynamics coupled with energy minimization techniques, operating on an Alliant FX 80 computer. Two different strategies were adopted for this simulated annealing (SA). As a first choice the undefined two loops were removed and the rest of the molecule was treated as three separate fragments. Simultaneously, as a second choice, these loops were built by using the available built-in database of FRODO (even though a few residues did not have reliable density), and the whole molecule was subjected to the SA procedure.

The initial R-factor before starting the simulated annealing was 47%. Conditions set were (1) the number of cycles of energy minimization was 240 with $\Delta f=0.05$ Å (Δf indicates how far any atom can move before the first derivative of the energy term due to diffraction data is updated), (2) heating stage of molecular dynamics, 0.5 ps, $T=4000^\circ\text{K}$, timestep= 1 fs, velocity scaling every 25 fs and Δf of 0.2 Å, (3) cooling stage of molecular dynamics, 0.25 ps, $T=300^\circ\text{K}$, timestep=1 fs, velocity scaling every 25 fs and Δf of 0.2 Å, and (4) with 150 cycles of energy minimization and $\Delta f=0.05$ Å.

-25-

The first cycle revealed a weak but continuous density in the above said surface loop regions, for both the options and the R factor dropped from 47% to 32%. The loops were built in and a second cycle of SA was done with 2.5 Å data. For the last cycle, the T was kept as 1000°K. Computed $4|F_o|-3|F_c|$ and $|F_o|-|F_c|$ maps revealed the missing residues in the loops. At the end of the SA refinement the R factor was 25%.

The model was then subjected to restrained Least Squares refinement program RESTRAIN (Moss and Morffew, 1982; Haneef *et al.*, 1985), running on the Allient FX 80 computer. The parameters refined include the Cartesian coordinates and a mean square displacement or isotropic thermal parameter (U_{iso}) for each non-hydrogen atom. All non-hydrogen atoms were refined with a fixed occupancy factor of unity. Minimum target interatomic restrain distances were used to remove unfavorable van der Waals contacts. No restraints between the U_{iso} values of neighboring atoms were applied. Planarity restraints were applied to the rings of histidine, phenylalanine, tryptophan and tyrosine residues, side chain carbonyls and amides, and to a lesser degree to peptide planes of the main chain. The chiral restraints were applied as distance restraints along the edges of the chiral tetrahedra. Progress was monitored by a calculation of the crystallographic R-factor

$$R = \frac{\sum ||F_o| - G| F_e||}{\sum |F_o|},$$

-26-

where G is scale factor. Structure factor amplitudes were weighted by the modified Cruickshank (1960, 1965) function.

5 The weights of the distance restraints at the end of the refinement were adjusted such that the r.m.s. deviations of the target values from the ideal values were as small as possible. Atomic coordinates, an overall scale and an overall temperature factor were refined for the first few
10 cycles and only later were individual isotropic temperature factors allowed to change.

At this stage, unidentified peaks in the difference Fourier maps were assigned to water molecules. A total of 55 such water molecules
15 were identified and included in subsequent refinement. The least squares refinement was performed progressively by increasing the resolution of the data from 2.5 Å to 2.0 Å. Throughout the refinement the weights for the
20 geometric restraint classes were varied in order to obtain a model with reasonable geometry and expected r.m.s. deviation. Additional 60 water molecules were identified during further cycles of refinement and remodeling to electron density maps.

25

-27-

EXAMPLE 2

Analysis of the Structure of IL-1 β

5 The final R-factor for reflections between 20
and 2.0 Å resolution is 0.19. Atomic coordinates
have been deposited with the Protein Data Bank
(Bernstein *et al.*, 1977). Finzell *et al.*, 1989
and Priestle *et al.*, 1989 also submitted their
10 coordinates simultaneously and a comparison of the
present structure (Fig. 2) with these two revealed
that all the three are almost identical with a few
deviations in the surface loops. The deviations
observed in the final model for bond lengths, bond
15 angles and for planar deviations are found to be
well within the ideal targeted variances.

Atomic isotropic mean-square displacement
parameters (B) were refined for all non-hydrogen
atoms including solvent oxygen atoms. The mean B
20 value for all the 1219 protein atoms is 38.1 Å²
and that of 115 solvent atoms is 67.3 Å²,
resulting in a mean B value of 40.7 Å² for all the
1334 atoms included in the refinement. As
expected, the main chain atoms have a lower mean B
25 value than side chain atoms. The regions of the
molecule showing the highest B values are mainly
in loops connecting β strands (residues 33-35,
49-54, 106-108 and 137-141) and residues in the
amino and carboxy termini regions. The same
30 characteristics of very high thermal fluctuations
in the same segments of this molecule has been
observed in the other two structures also.

Of the 115 solvent molecules identified,
there are nine internal water molecules held
35 tightly within the cavities of the protein and

-28-

51 waters in the first solvation shell of the protein, interacting directly with the protein's main chain or side chains. The remaining waters are either in the second shell or in between the symmetry related molecules in the crystal lattice. Crystal packing analysis shows that long uninterrupted solvent channels run parallel to the crystallographic a and b axes. As expected almost all the charged residues show a much larger accessibility than the mean, while hydrophobic residues Val, Leu, Ile and Phe are less accessible than the mean. Glycines and prolines display a high mean accessibility. All the tyrosines are exposed and make hydrogen bonding contacts with solvent molecules.

-29-

EXAMPLE 3

Site Directed Mutagenesis of IL-1 β

5 An IL-1 β expression plasmid for site-directed
mutagenesis is constructed as described in
Kamogashira et al., Biochem. Biophys. Res. Comm.
150, 1106 (1988). This expression plasmid
10 contains the coding region of IL-1 β under the
control of trp promoter. The plasmid also
contains the intergenic region of the phage f1 as
used for isolation of single stranded DNA for
site-directed mutagenesis and for expression of
IL-1 β protein.

15 The site directed mutagenesis of Glu25 to Ala
is then conducted in accordance with the
techniques of Zollen et al., Methods in
Enzymology, Academic Press, Wu, Grossman and
Moldane eds., Vol. 100, pp. 468-500 (1983).
20 Appropriately mutated oligonucleotides are
phosphorylated, and then mixed with appropriate
amounts of single stranded DNA template from the
expression vector, DTT, dNTPs, ATP, hybridization
buffer, T4 DNA ligase and Klenow DNA polymerase I
25 as described in Zollen et al. and Kamogashira et
al. Samples from the ligation mixture are then
used to transform competent E. coli MV 1304 cells.

Colonies containing mutated plasmids are
identified by hybridization with 5'-³²P-labeled
30 oligonucleotides. Plasmid DNA is subjected to
nucleotide sequence analysis to confirm the
presence of the desired mutation by the methods of
Sanger et al., Proc. Natl. Acad. Sci. USA 74, 5463
(1977).

-30-

The mutant IL-1 β protein is prepared by induction of the trp promoter after tryptophan starvation of the E. coli with mutant plasmid. Growth of E. coli is in a suitable medium such as M9 medium containing 0.4% glucose and 1.0% casamino acid. Mutant protein is recovered by standard techniques set forth in Laemmli, Nature 227, 680 (1970) and Kahn et al., Methods in Enzymology, Academic Press, Wu, Grossman and Moldane eds, Vol. 68, pp. 268-280 (1979).

Other mutant forms of IL-1 β any of the other disclosed mutations may be produced using appropriately mutated oligonucleotides in the above procedure. As discussed in the specification, some of these mutant forms of IL-1 β will have IL-1 β antagonist activity and some will have IL-1 β agonist activity.

-31-

EXAMPLE 4

Binding Analysis of IL-1 β Mutant

5 An IL-1 receptor binding analysis of the
IL-1 β mutant of Example 3 is performed using the
published procedure of Dower et al., Nature 324,
341 (1986). This procedure utilizes the IL-1
10 receptors on human dermal fibroblast cells.
Briefly, 10 μ l of the mutant IL-1 β of Example 3 in
10 μ l of phosphate (0.015M) buffered saline (0.15M)
pH 7.2 is added to 10 μ l of sodium borate (0.1M)
buffered saline (0.15M) pH 8.5. The mutant IL-1 β
15 is then reacted with 1 mCi of Bolton Hunter
reagent according to the manufacturer's
instructions for 12 hours at 8°C. Then, 30 μ l of
2% gelatin and 5 μ l of 1M glycine ethyl ether is
added, and the mutant IL-1 β separated from the
unreacted reagent on a 1 μ l bed volume Biogel P6
20 (Biorad) column. Approximately 50-60%
incorporation of the radiolabel is observed.
Precipitation of the ¹²⁵I-IL-1 β mutant in 1%
gelatin carrier using 10% trichloroacetic acid on
gel filtration column shows that >98% of the ¹²⁵I
25 label is protein bound after P6 purification.

Human dermal fibroblasts are obtained from
the American Type Tissue Culture Collection (CRL
1229, passage 5) and propagated in monolayer
cultures in DMEM 10% fetal calf serum. The
30 fibroblasts are harvested for the binding assay by
treatment with PBS containing EDTA (0.5mM) to
avoid proteolysis of the receptor.

The fibroblast cells are then incubated with
¹²⁵I-labelled mutant IL- β and unlabelled IL-1 β in
35 150 μ l of RPMI 1640 with 1% BSA, 0.1% sodium azide

-32-

and 20 Mm HEPES pH 7.4 for 2 hours at 8°C on a rocker platform in round bottom well microtitre plates. Cells and bound radiolabelled mutant IL-1 β are then separated from unbound label by centrifuging 60 μ l aliquots of the reaction mixtures through 200 μ l of phthalate oils in 400 μ l polyethylene centrifuge tubes and excising the tips with a razor blade as taught by Segal et al., J. Immun. 118, 1338 (1977).

Equilibrium binding data are analyzed using a bimolecular binding model as described by Dower et al., J. Exp. Med. 162, 501 (1985). The values for nonspecific binding are determined by fitting a straight line passing through the origin to data obtained from binding of the ¹²⁵I-labelled mutant IL-1 β to human fibroblast cells in the presence of a 100-fold molar excess of unlabelled IL-1 β . The mutant IL-1 β from Example 3 is found to have almost a 100% binding profile to the human fibroblast cells. However, other IL-1 β mutants wherein the Lys103 has been mutated will have a significantly lower binding profile due to the mutation at the receptor binding surface.

-33-

EXAMPLE 5

Bioassay of IL-1 β Mutant

5 The level of IL-1 β activity of a composition
is commonly determined by its ability to inhibit
the growth of human melanoma cells A375.S1. This
property of IL-1 β is referred to as its growth
inhibitory factor (GIF) activity. One GIF unit is
10 defined as the reciprocal of the sample dilution
necessary to yield about a 50% cytostasis or
cytolysis in 4 day old cultures of the melanoma
cells.

 The IL-1 β mutant of Example 3 is used in this
15 assay as described in Lackman et al., J. Immunol.
136, 3098 (1986), and exhibits a decrease in GIF
activity as compared to the GIF activity of
IL-1 β . Other antagonist mutants of IL-1 β are
expected to exhibit similar decreased GIF
20 activity, whereas agonist mutants of IL-1 β are
expected to exhibit GIF activity at a similar
level to that of IL-1 β .

 While the invention has been described in
25 connection with specific embodiments thereof, it
is understood that the invention is capable of
further modifications. This disclosure is
intended in an illustrative rather than in a
limiting sense, as it is contemplated that
30 modifications will readily occur to those skilled
in the art, within the spirit of the invention and
the scope of the appended claims.

5 (i) APPLICANT: VEERAPANDIAN, BALASUBRAMANIAN

(ii) TITLE OF INVENTION: Modified
Interleukin-1 β

10 (iii) NUMBER OF SEQUENCES: 1

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Venable, Baetjer,
Howard & Civiletti

15 (B) STREET: 1201 New York Avenue, N.W.
Suite 1000

(C) CITY: Washington

(D) STATE: DC

(E) COUNTRY: USA

20 (F) ZIP: 20005

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk

(B) COMPUTER: IBM PC compatible

25 (C) OPERATING SYSTEM: PC-DOS/MS-DOS

(D) SOFTWARE: PatentIn Release #1.0,
Version #1.25

(vi) CURRENT APPLICATION DATA:

30 (A) APPLICATION NUMBER:

(B) FILING DATE:

(C) CLASSIFICATION:

-35-

(viii) ATTORNEY/AGENT INFORMATION:

- (A) NAME: Highet, David W.
(B) REGISTRATION NUMBER: 30,265
(C) REFERENCE/DOCKET NUMBER:
20509-87145

5

(ix) TELECOMMUNICATION INFORMATION:

- (A) TELEPHONE: 202-962-4854
(B) TELEFAX: 202-962-8300

10

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 5 amino acids
(B) TYPE: amino acid
(C) TOPOLOGY: linear

15

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: No

20

(vi) ORIGINAL SOURCE:

- (A) ORGANISM:
(B) STRAIN:

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Glu Cys Met Met Lys

-36-

WHAT IS CLAIMED IS:

1. A modified interleukin-1 β polypeptide with altered interleukin-1 activity, said modified
5 interleukin-1 β having at least one mutation that affects at least one target amino acid in the beta barrel core portion of the interleukin-1 β structural formula.
- 10 2. The modified interleukin-1 β of claim 1 wherein the target amino acid is selected from the group consisting of Glu25, Lys103, Cys8, Met44 and Met148.
- 15 3. The modified interleukin-1 β of claim 2 wherein the mutation is a mutation of the target amino acid.
- 20 4. The modified interleukin-1 β of claim 2 wherein the mutation is a mutation of an amino acid proximate to the target amino acid.
- 25 5. The modified interleukin-1 β of claim 3 wherein the mutation is the mutation of Glu25 to Ala.
6. The modified interleukin-1 β of claim 3 wherein the mutation is the mutation of
Lys103 to Ala.
- 30 7. The modified interleukin-1 β of claim 3 wherein the mutation is the mutation of Cys8, Met44 and/or Met148 to Ala or Gly.

-37-

8. The modified interleukin-1 β of claim 4 wherein the mutation is the mutation of Ser21 to Arg.
- 5 9. A protein with interleukin-1 β activity comprising a polypeptide with a Lys at one terminal end thereof, a Glu at the other terminal end thereof, and a sulfur cluster of -Cys-Met-Met- therebetween.
- 10 10. The protein of claim 9 having the amino acid sequence of SEQ ID NO.1.
- 15 11. A protein which enhances the affects of interleukin-1 β agonists comprising a polypeptide with a sulfur cluster of -Cys-Met-Met- therein.
- 20 12. The protein of claim 11 comprising the tripeptide -Cys-Met-Met-.
13. An expression system which will produce the modified interleukin-1 β of claim 1.
- 25 14. An expression system which will produce the modified interleukin-1 β of claim 5.
15. An expression system which will produce the modified interleukin-1 β of claim 6.
- 30 16. An expression system which will produce the modified interleukin-1 β of claim 7.
- 35 17. An expression system which will produce the modified interleukin-1 β of claim 8.

-38-

18. An expression system that will produce the protein of claim 9.
- 5 19. An expression system that will produce the protein of claim 10.
20. An expression system that will produce the protein of claim 11.
- 10 21. An expression system that will produce the protein of claim 12.
22. A method of treating inflammatory disease in mammals comprising the administration of a therapeutically effective amount of a compound of claim 1.
- 15 23. A modified polypeptide composition having a barrel portion in its structural formula, said modified polypeptide composition having at least one mutation that affects a target amino acid in the barrel portion, said mutation resulting in an altered activity of the modified polypeptide composition as compared to the activity of the polypeptide composition prior to modification.
- 20 24. The modified polypeptide composition of claim 23 selected from the group consisting of interleukin-1 β , interleukin-1 α , fibroblast growth factor and tumor necrosis factor.
- 25 30

1 / 2




FIG. 1A




FIG. 1B

2/2





FIG. 2

SUBSTITUTE SHEET

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US92/00662

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ³		
According to International Patent Classification (IPC) or to both National Classification and IPC		
IPC (5): CO7K 13/00; A61K 37/02; C12P 21/02; C12N 15/70 US CL : 530/351,350,395; 435/69.1,69.5,69.52,252.3,320.1; 424/85.1; 514/2		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁴		
Classification System	Classification Symbols	
U.S.	530/351,350,395,399; 435/69.1,69.5,69.52,252.3,320.1; 424/85.1,,85.2; 514/2,8; 930/140,145,120	
Documentation Searched other than Minimum Documentation to the extent that such Documents are included in the Fields Searched ⁵		
Please See Attached Sheet.		
III. DOCUMENTS CONSIDERED TO BE RELEVANT ¹⁴		
Category*	Citation of Document, ¹⁶ with indication, where appropriate, of the relevant passages ¹⁷	Relevant to Claim No. ¹⁸
X/Y	Journal Biological Chemistry, Vol. 265, No. 11, issued 1990, Gehrke et al., "A Point Mutation Uncouples Human Interleukin-1 β Biological Activity and Receptor Binding", see pages 5922-25.	1,13,22-24/2-12,14-21
X/Y	European Journal of Biochemistry, Vol. 179, issued 1989, Wingfield et al., "Preparation, Characterization and Application of Interleukin-1 β Mutant Proteins With Surface-Accessible Cysteine Residues", see pages 565-571	1,13,22-24/2-12,14-21
X/Y	EP,A, 0,923,967, (Nakai et al.), 23 September 1987, see pages 1-7 and 47-49.	1 3,7,13,16,22-24/1-24
X/Y	Biochemical and Biophysical Research Communications, Vol. 150, No. 3, issued 1988, Kamogashira et al., "Site-Specific Mutagenesis of the Human Interleukin-1 β Gene: Structure-Function Analysis of the Cysteine Residues."	1 3,7,13,16,22-24/1-24
* Special categories of cited documents:¹⁶ "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search ²	Date of Mailing of this International Search Report ²	
18 MAY 1992	04 JUN 1992	
International Searching Authority ¹	Signature of Authorized Officer ²⁰	
ISA/US	 Garnette D. Draper, Primary Examiner	

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET		
X/Y	Chemical Abstracts, Vol. 114, No. 11, issued 1990, Mizuno et al., "Interleukin-1 beta Derivatives Labeled With Radioactive Iodine and Their Preparation", see abstract No. 99851k, JP 88-324489, 21 December 1988.	1,3,7,13,16,22 -24/1-24
X/Y	Chemical Abstracts, Vol. 114, No. 19, issued 1990, Kamoto et al., "Human Interleukin-1 beta. Derivatives Recombinant Manufacture as Pharmaceuticals for Treatment of Disorders Associated With Excess Interleukin-1 beta." see abstract No. 179735r, JP 89-274339, 20 October 1989.	1,3,7,13,16,22 -24/1-24
V. ☐ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE¹		
1. ☐ Claim numbers , because they relate to subject matter (1) not required to be searched by this Authority, namely: 2. ☐ Claim numbers , because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out (1), specifically: 3. ☐ Claim numbers , because they are dependent claims not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).		
VI. ☒ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING²		
This international Searching Authority found multiple inventions in this international application as follows: Group I, Claims 1-12 and 22 to various mutants of IL-1β and use of it; 530/351 Group II, Claims 13-21 to expression host; 435/252.3 Group ~~III~~, Claims 23-24 to <u>any</u> modified polypeptides; 530/350 1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application. 2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims: 3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers: 4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the international Search Authority did not invite payment of any additional fee. Remark on protest ☐ The additional search fees were accompanied by applicant's protest. ☐ No protest accompanied the payment of additional search fees.		

FURTHER INFORMATION CONTINUED FROM PREVIOUS SHEETS

II. FIELDS SEARCHED

Other Documents Searched:

Computer data base search; Files

CA, 5, 16, 35, 50, 60, 73, 76, 77, 103, 144, 149, 151, 155, 156, 157, 159, 357, 399, 434, 440, 545; For:
IL-1 β antagonist/agonist; mutant for blocking receptor